Downstate 20outside 202
Parkside 20pic 20logo

Parkside Scientific Inc.

Readying drug cures for deadly cancers (Prostate; Triple-Neg. Breast) and other diseases (IBD, MS) by novel epigenetic approach of turning genes "on/off".

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York, NY, US
  • Currency USD
  • Founded June 2013
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

Parkside designs and develops drugs based on pioneering epigenetic work of our Founder/CSO Ming-Ming Zhou, who continues to Chair Mount Sinai's Pharmacological Sci Dept. (30 labs). Leveraging existing multi-$MM equipment and trained scientists, Parkside directs sophisticated R&D Agmts with Zhou Lab at Mount Sinai and First Bethune Hospital (China). In-house focus on unique proprietary drug design. Efficiently outsource mundane work to CROs.


  • 6429bc4c 8bea 4cd6 998d 88592f8474d6
    Chief Business Officer & General Counsel

    Wide ranging career in law and business spanning over 25 years. Former General Counsel to Carl Icahn & VP Icahn Holdings; Co-Founder/Chief Business Officer of pioneer $700MM activist fund Greenway Partners; financial adviser to listed biotech company Biotime, Inc.; managing member, Verde Asia Fund; among initial trustees of Nat'l Alliance for Autism Research. Expertise in financing and operating public and private companies.

  • 8708953b 6951 4d44 b52e 136f673940fa
    Founder & Chief Scientist

    Internationally recognized expert in structural and chemical biology, NMR spectroscopy of protein structure-function and rational small-molecule design. In addition to directing drug discovery at Parkside, Dr. Zhou is currently Professor and Chairman of the Department of Pharmacological Sciences and Co-Director of the Experimental Therapeutics Institute at the Icahn School of Medicine at Mount Sinai, as well as Professor Oncological Sciences.

  • 87e8cb67 9691 4dc3 89cf 7fd0cf7e9c09
    Research Director/US

    Dr. Zhang oversees Parkside's Lab at Downstate Biotech Center, trains scientific staff and coordinates drug development work with Zhou Lab (Sinai), First Bethune and CROs. Expertise in biochemistry, cell and structural biology. Like Dr. Zhou, Dr. Zhang’s work over the past 15 years has largely centered on understanding Bromodomain proteins and how they regulate gene expression. Dr. Zhang has published over 30 peer-reviewed publications.